Lymphoma
Conditions
Interventions
Treatment group:Rituximab + Pomalidomide (RP)
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Gender: No restriction; Age: >=60 years; or =1 criterion required): (1) Hemoglobin 10 cm), or massive splenomegaly (>=6 cm below left costal margin); (4) B symptoms: Fever >38°C (persistent/recurrent for 2 weeks, non-infectious), night sweats, or >10% weight loss in 6 months; (5) Rapid progression (e.g., lymphocyte doubling time =3 months.
Exclusion criteria
Exclusion criteria: 1. Diagnosis or treatment for malignancies other than B-NHL within the past year (including active central nervous system lymphoma); 2. Clinical evidence of transformation to large cell lymphoma or progression to prolymphocytic leukemia (PLL); 3. Non-lymphoma-related hepatic or renal impairment: Alanine aminotransferase (ALT) >3× upper limit of normal (ULN); Aspartate aminotransferase (AST) >3× ULN; Total bilirubin (TBIL) >2× ULN; Serum creatinine >1.5× ULN; 4. Other severe medical conditions that may interfere with the study (e.g., uncontrolled diabetes, gastric ulcers, significant cardiopulmonary diseases, etc.). Final determination is at the investigator's discretion. 5. Severe or uncontrolled infections; 6. Central nervous system involvement or clinically manifest neurological dysfunction; 7. Major surgery within the past 30 days (excluding lymph node biopsy); 8. Pregnant or lactating women, or women of childbearing potential not using contraception; 9. Known hypersensitivity to any study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate, ORR;Complete response rate, CRR;Overall survival rate;Molecular biology remission rate;Duration of tumor remission;Treatment related side effects; | — |
Countries
China
Contacts
Public ContactLi Zengjun
Shandong Cancer Hospital
Outcome results
None listed